2008-05-31

/K I L L K I L L K I L L -- Merck Serono/


We are advised by Merck Serono that journalists and other readersshould disregard the news release "Erbitux Significantly ProlongsSurvival in 1st-Line Treatment of Non-Small Cell Lung Cancer"NYSE:SRA, issued today due to premature release. This release willbe reissued at a later date.

ots Originaltext: Merck SeronoIm Internet recherchierbar: http://www.presseportal.de

Contact:Contact: Dr. Raphaela Farrenkopf, Phone +49-6151-72-2274

Merck Serono

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs

News

/K I L L K I L L K I L L -- Merck Serono/

Medizin-News